The prognostic impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio on patients with small cell lung cancer receiving first-line platinum-based chemotherapy: a systematic review and meta-analysis
Authors:
Open Access
- 22 December 2024
- journal article
- review article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 24 (1) , 1-11
Abstract
The prognostic significance of Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) in Small Cell Lung Cancer (SCLC) patients receiving platinum-based chemotherapy is debated. This study aims to elucidate their roles in survival outcomes. A systematic search across PubMed, Embase, Web of Science, and Cochrane Library identified relevant studies. The Newcastle-Ottawa Scale (NOS) evaluated study quality. Meta-analysis was conducted using random-effects and fixed-effects models, supplemented by sensitivity analysis. A total of 11 studies with 3,634 SCLC patients were included. Patients with high NLR had significantly decreased overall survival (OS) (HR = 1.39, 95% CI: 1.18–1.59, P < 0.001) and progression-free survival (PFS) (HR = 1.52, 95%CI: 1.27–1.78, P < 0.001). The OS was not statistically different between high and low PLR groups (HR = 1.13, 95%CI: 0.84–1.43, P = 0.265). Subgroup analysis revealed that OS in high NLR group was significantly lower across different strata, and OS in the high PLR group was significantly lower among patients with limited-stage SCLC (LS-SCLC) and populations with a PLR cutoff value < 160. High NLR is associated with poor OS and PFS in patients with SCLC receiving first-line platinum-based chemotherapy. PLR does not significantly impact OS, except in LS-SCLC patients and populations with a PLR cutoff value < 160. These findings require further validation from prospective studies.Keywords
This publication has 28 references indexed in Scilit:
- External Validation of a Survival Score for Limited-Stage Small Cell Lung Cancer Patients Treated with ChemoradiotherapyLung, 2020
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trialThe Lancet, 2019
- Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancerLung Cancer, 2019
- Prognostic Significance of Total Lymphocyte Count, Neutrophil-to-lymphocyte Ratio, and Platelet-to-lymphocyte Ratio in Limited-stage Small-cell Lung CancerClinical Lung Cancer, 2019
- Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancerRadiotherapy and Oncology, 2018
- Neutrophil-to-Lymphocyte Ratio Predicts Outcome in Limited Disease Small-cell Lung CancerLung, 2017
- The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysisEuropean Urology Focus, 2016
- High pretreatment neutrophil–lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancerClinical and Translational Oncology, 2015
- The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancerBritish Journal of Cancer, 2014
- Prognostic Significance of Pretreatment Laboratory Parameters in Combined Small-Cell Lung CancerCell Biochemistry and Biophysics, 2014